Clinical trial announcements: antisense for restenosis

The following are announcements of the first clinical trial with a Morpholino-peptide conjugate.

http://www.bioresearchonline.com/article.mvc/AVI-BioPharma-Announces-Initiation-Of-0001

Start of press release:

AVI BioPharma Announces Initiation Of Clinical Trial Of Next Generation Drug Eluting Stent By Partner Global Therapeutics

November 11, 2008

AVI BioPharma, Inc., a developer of RNA-based drugs, recently announced that its partner Global Therapeutics, a Cook Medical company, has initiated the world’s first clinical trial of a drug eluting stent that uses a PPMO (peptide-conjugated morpholino phosphorodiamidate oligomer)-based RNA therapeutic agent aimed at silencing C-MYC, one of the genes responsible for causing arteries to reclose after stenting (restenosis).

—————————————————————

http://www.cookmedical.com/newsDetail.do?id=3910

Another from Cook Medical about the same trial:

Global Therapeutics Initiates Trial of Next Generation Drug-Eluting Stent Using RNA Therapeutic Agent to Treat Coronary Artery Disease

November 10, 2008

Broomfield, Colo., November 10, 2008 — Global Therapeutics, a leading developer of innovative solutions for the cardiology market, today announced initiation of the world’s first clinical trial of a drug eluting stent that uses an antisense RNA therapeutics agent aimed at silencing one of the genes (c-myc) responsible for causing arteries to reclose after stenting (restenosis).